Among these entries, ranging from 1995 to 2021, 24 concerned breast cancer trials using DHA + EPA/Rx showed that n-3 LC-PUFAs, with combinational treatment by adjuvant therapy or using single treatment in a preventive way or as treatment, (i) targeted SCD-1 for reducing breast cancer risk in obese postmenopausal women [101], (ii) changed n-3:n-6 ratio at the breast tissue in pre-menopausal women [102], and (iii) reduced incidence of paclitaxel-induced peripheral neuropathy [103]. The gene discussed is SCD; the disease is breast carcinoma.